US Bancorp’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

US Bancorp’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,559	Closed	-$71K	–	4289
2021 Q3	$71K	Sell	3,559 -17,311	-83%	-$478K	﹤0.01%	2473
2021 Q2	$779K	Buy	20,870 +1,636	+9%	+$50.1K	﹤0.01%	1325
2021 Q1	$492K	Sell	19,234 -214	-1%	-$5.47K	﹤0.01%	1504
2020 Q4	$428K	Buy	19,448 +2,254	+13%	+$49.6K	﹤0.01%	1523
2020 Q3	$309K	Buy	17,194 +13,159	+326%	+$272K	﹤0.01%	1579
2020 Q2	$102K	Buy	4,035 +1,060	+36%	+$22.8K	﹤0.01%	2096
2020 Q1	$55K	Buy	2,975 +1,775	+148%	+$34.5K	﹤0.01%	2322
2019 Q4	$27K	Buy	+1,200	New	+$24.1K	﹤0.01%	2767

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

US Bancorp's DRNA Position: Q4 2021 in Review

US Bancorp sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 3,559 shares — an estimated $71K sold.

US Bancorp first reported a position in DRNA in Q4 2019 and held it in 8 quarters. The position peaked at $779K in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

US Bancorp reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
US Bancorp sold 3,559 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $71K.
US Bancorp first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2019 and held it in 8 quarters.
US Bancorp's Dicerna Pharmaceuticals, Inc. position peaked at $779K in Q2 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on US Bancorp's 13F filing for Q4 2021, filed 11 Feb 2022.